Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
about
Translatability scoring in drug development: eight case studiesGetting the balance right: Established and emerging therapies for major depressive disordersVilazodone for the Treatment of Depression: An UpdateACS chemical neuroscience molecule spotlight on viibryd (Vilazodone)Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapyCharacterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies.Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trialsClinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms.A review of vilazodone, serotonin, and major depressive disorder.Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain.Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorderVilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trialEfficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.Evaluation of the efficacy and safety of vilazodone for treating major depressive disorderThe role of serotonin receptor subtypes in treating depression: a review of animal studiesEfficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderA 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder.The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.Psychopharmacological Practice: The DSM Versus The Brain.Multi-modality: a new approach for the treatment of major depressive disorder.Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials.The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.The Black Book of Psychotropic Dosing and Monitoring.Assessment and management of sexual dysfunction in the context of depression.Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
P2860
Q22241760-DC3130DE-5931-424F-9F7D-445F66C58D47Q24610225-2808D2CD-C95D-4C9B-A922-92AB7BA4DC7CQ26745605-668C9970-E2E4-41CF-B7B7-919BFE628D19Q26860359-D1105ABE-F305-4D40-95DA-7A48C94C32E3Q28083651-551FFD29-CF08-4985-AF07-A24CDA786325Q30276416-FA5EE317-44C1-4C74-900F-B76D444B45CBQ30384691-EDCEF13F-88CA-4CD9-8763-D382AD9C7309Q30468292-4C159E23-B5B3-4A98-BF36-A895C6480EF9Q30491758-FFE9185E-F306-4DFC-8235-0B4A85D9E842Q33721191-9EFB2B38-C3EA-4836-8EFF-B46794C951A2Q33721197-6AF6867E-4B99-4C27-9FB9-398529DFEEA2Q34293216-9E34EE6A-59D6-44B7-AC52-8989903EABA9Q34293892-1A22A8CA-ECEB-4850-99D5-385953F8C452Q34672417-620C007E-9A23-41D4-8BCA-4891836EDF81Q34675188-A8F88077-87A4-4C71-8597-ED1D1F6FF354Q35038925-99D0A8A0-A903-493C-9584-2AB8D713B725Q35038928-E3A99A46-7655-476B-AC24-FDD527EC3E0AQ35330385-1D5764D8-A34A-4799-811E-62C3E9F4FF6AQ35934859-2BC63954-59FD-42ED-A649-7FBEE0A6231EQ36031101-7FC7CB16-90A9-4C2B-A9B3-ED37593524D5Q36216847-80ACB31B-6D04-4AE0-A7A7-32A7190721C3Q36332538-4C1D00A4-06C4-4EF7-BB83-90E18B071DA0Q36366194-DF012011-011E-43E1-B642-7A1BE147CD7AQ36722951-7FF925CF-5D41-4BDC-B843-0A6D2D95F0C0Q36825752-DA06B8C1-F53D-4D5B-A022-9D99B31C4DA2Q36841553-85CA0FC0-00E4-4229-829F-C883EF776E85Q36896252-43A27BBC-41D1-4F54-8ADD-91D9301CE950Q37078931-C45EEEDB-1D40-4230-BA0E-74ECAEC5E9E5Q37115879-CFDFFD23-CBB4-4E16-9F13-6BEC39393785Q37299972-ED33F55A-38B2-4AE0-92EA-4D7B9ABB6605Q37503551-C7B53DE9-38EE-4902-AE3C-64F57C61C780Q37514703-FC36AC99-2728-461A-9122-0EDB02D65E5DQ42061953-B24F9313-7BD4-4E6C-8CB1-CCC594DCC2C8Q47141387-F8D6D96C-8686-4D11-87EA-818E47677802Q47642128-19F6E138-C399-4E92-AB38-05195F787610Q47653061-620902C2-E9BD-4219-BED3-A9A1C1A271CBQ47906098-6F5ED1DA-6A5C-42C4-A968-C187486085C1Q52613387-63ED8C82-41B5-4F79-970B-6743F2B6A063Q53414630-3B525AA2-FC5F-48EF-90F9-AEC04197FF9EQ59128329-CE155207-8C38-4E3C-A962-6E360EA77C16
P2860
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@ast
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@en
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@nl
type
label
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@ast
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@en
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@nl
prefLabel
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@ast
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@en
Evidence for efficacy and tole ...... ind, placebo-controlled trial.
@nl
P2093
P356
P1476
Evidence for efficacy and tole ...... lind, placebo-controlled trial
@en
P2093
Carol R Reed
Donald S Robinson
Heidi Whalen
Karl Rickels
Maria Athanasiou
Michael Gibertini
P304
P356
10.4088/JCP.08M04637
P577
2009-03-10T00:00:00Z